8 June 2018

Contents

Editorial

• 08 June 2018: vol 19 no 10: DTG alert and PK reports

Treatment alerts

• BHIVA statement on potential safety signal in infants born to women conceiving on dolutegravir

• ViiV Dear Doctor letter: Neural tube defects reported in infants born to women exposed to dolutegravir at the time of conception

Supplements

• Introduction to ART (May 2018)

Conference reports

• 19th International Workshop on Clinical Pharmacology, 22–24 May 2018, Baltimore

• Dolutegravir 50 mg twice daily sufficient with rifampicin but levels reduced significantly with 100 mg once daily 

• Vaginal ring reduces efavirenz but not atazanavir exposures 

• Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations  

Antiretrovirals

• EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option

Side effects

• Boosted darunavir is associated with higher cardiovascular risk in D:A:D study, but not atazanavir

HIV prevention and transmission

• Broad PrEP access in Australia reduces HIV infections even with reduced condom use by people not on PrEP

• Webcasts on PrEP and women

Cure-related research

• Online database of more than 200 studies on HIV cure research

• Community survey on treatment interruptions (ATIs) in cure research

On the web

• Sexual identity and HIV

• Modern ART in Africa: new resources

PDFs

• 08 June 2018: vol 19 no 10